Systemic corticosteroid therapy may delay viral clearance in patients with middle east respiratory syndrome coronavirus infection

American Journal of Respiratory and Critical Care Medicine

Volumn 197, Issue 6, 2018, Pages 700-701

  Hui, David S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; INTERFERON; LOPINAVIR; VIRUS RNA;

ASSISTED VENTILATION; CORTICOSTEROID THERAPY; EDITORIAL; HUMAN; INFLUENZA A (H1N1); MIDDLE EAST RESPIRATORY SYNDROME; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RESPIRATORY TRACT INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC THERAPY; VIRAL CLEARANCE; VIRUS PNEUMONIA; VIRUS SHEDDING; CORONAVIRUS INFECTION; CRITICAL ILLNESS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS;

ADRENAL CORTEX HORMONES; CORONAVIRUS INFECTIONS; CRITICAL ILLNESS; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS;

EID: 85045188253     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201712-2371ED     Document Type: Editorial

References (15)

1. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet 2015;386:995-1007.
2. Zhou J, Chu H, Li C, Wong BH, Cheng ZS, Poon VK, et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J Infect Dis 2014;209:1331-1342.
3. Alsaad KO, Hajeer AH, Al Balwi M, Al Moaiqel M, Al Oudah N, Al Ajlan A, et al. Histopathology of Middle East respiratory syndrome coronovirus (MERS-CoV) infection - clinicopathological and ultrastructural study. Histopathology 2018;72:516-524.
4. Arabi YM, Al-Omari A, Mandourah Y, Al-Hameed F, Sindi AA, Alraddadi B, et al.; Saudi Critical Care Trial Group. Critically ill patients with the Middle East respiratory syndrome: a multicenter retrospective cohort study. Crit Care Med 2017;45:1683-1695.
5. Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, et al.; Saudi Critical Care Trial Group. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med 2018;197:757-767.
6. Lee N, Allen Chan KC, Hui DS, Ng EK, Wu A, Chiu RW, et al. Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J Clin Virol 2004;31: 304-309.
7. Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev 2016;3:CD010406.
8. Cao B, Gao H, Zhou B, Deng X, Hu C, Deng C, et al. Adjuvant Corticosteroid Treatment in Adults With Influenza A (H7N9) Viral Pneumonia. Crit Care Med 2016;44:e318-e328.
9. Li H, Yang SG, Gu L, Zhang Y, Yan XX, Liang ZA, et al.; National Influenza A(H1N1)pdm09 Clinical Investigation Group of China. Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia. Influenza Other Respir Viruses 2017;11:345-354.
10. Lee N, Leo YS, Cao B, Chan PK, Kyaw WM, Uyeki TM, et al. Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients. Eur Respir J 2015;45: 1642-1652.
11. Oh MD, Park WB, Choe PG, Choi SJ, Kim JI, Chae J, et al. Viral load kinetics of MERS coronavirus infection. N Engl J Med 2016;375: 1303-1305.
12. Kang CK, Song KH, Choe PG, Park WB, Bang JH, Kim ES, et al. Clinical and epidemiologic characteristics of spreaders of Middle East respiratory syndrome coronavirus during the 2015 outbreak in Korea. J Korean Med Sci 2017;32:744-749.
13. International Severe Acute Respiratory and Emerging Infection Consortium and Public Health England. Treatment of MERS-CoV: information for clinicians: clinical decision-making support for treatment of MERS-CoV patients, version 4.0. 2017 Aug 16 [accessed 2017 Aug 17]. Available from: https://www.gov.uk/ government/uploads/system/uploads/attachment-data/file/638628/ MERS-CoV-guidance-for-clinicians.pdf.
14. Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L, et al. Treatment with lopinavir/ritonavir or interferon-b1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 2015;212:1904-1913.
15. Choe PG, Perera RAPM, Park WB, Song KH, Bang JH, Kim ES, et al. MERS-CoV antibody responses 1 year after symptom onset, South Korea, 2015. Emerg Infect Dis 2017;23: 1079-1084.